Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors

GÜMÜŞ, MAHMUT; Bilici, Ahmet; Odabas, Hatice; Ustaalioglu, Bala; Kandemir, Nurten; Demirci, Umut; Cihan, Sener; Bayoglu, Ibrahim; Ozturk, Turkan; Turkmen, Esma; Urakci, Zurat; ŞEKER, MEHMET; Gunaydin, Yusuf; Selcukbiricik, Fatih; Turan, Nedim; Sevinc, Alper

doi:10.1007/s00345-016-1964-6

Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors

Atıf İçin Kopyala

GÜMÜŞ M., Bilici A., Odabas H., Ustaalioglu B. B. O. , Kandemir N., Demirci U., ...Daha Fazla

WORLD JOURNAL OF UROLOGY, cilt.35, ss.1103-1110, 2017 (SCI İndekslerine Giren Dergi)

Cilt numarası: 35 Konu: 7
Basım Tarihi: 2017
Doi Numarası: 10.1007/s00345-016-1964-6
Dergi Adı: WORLD JOURNAL OF UROLOGY
Sayfa Sayıları: ss.1103-1110

Özet

Background Currently, it is accepted that risk assessment of clinical stage I (CS I) nonseminomatous germ cell tumors (NSGCT) patient is mainly dependent on the presence of lymphovascular invasion (LVI). Initial active surveillance, adjuvant chemotherapy and retroperitoneal lymph node dissection (RPLND) are acceptable treatment options for these patients, but there is no uniform consensus. The purpose of this study was to compare outcomes of active surveillance with adjuvant chemotherapy.